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Abstract 
Purpose: To determine the association of osteopontin (OPN) polymorphisms with ankylosing 
spondylitis (AS). 
Methods: A total of 120 cases diagnosed with AS and 106 age- and sex-matched healthy controls were 
recruited. All the patients were human leukocyte antigen (HLA)-B27 positive. Three single nucleotide 
polymorphisms were genotyped using direct sequencing 
Results: The T allele at -443 SNP had significantly higher frequency in AS patients (0.1875) than the 
controls (0.1085, p < 0.01). The rate of CT+TT genotype in AS patients was significantly higher than 
those with CC genotype compared with the control (p < 0.01). 
Conclusion: SNP at -443 of OPN gene can serve as a candidate genetic marker to evaluate the risk of 
AS, thus indicating that subjects who carry T allele have a significantly higher risk of developing AS. 
 
Keywords: Genetic polymorphism, Ankylosing spondylitis, Osteopontin, Sequencing 
 
Tropical Journal  of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, 
International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African 
Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals 




Ankylosing spondylitis (AS) is a chronic 
inflammatory disorder characterized by 
inflammation in the spine and sacroiliac joints 
causing initial bone and joint erosion and 
subsequent ankylosis [1]. Most patients develop 
first symptoms of AS younger than 30 years of 
age [2]. More recent studies have shown that 
structural damage at initial presentation is the 
best predictor of further damage [3-5]. 
 
Osteopontin (OPN) is well known as a major 
non-collagenous protein related to bone 
remodeling [6-7].The expression of OPN in 
different cell types was significantly influenced by 
transcription factors, and the genetic 
polymorphisms of the promoter [8]. Previous 
studies showed that OPN inhibited nucleation, 
growth, and aggregation of calcium oxalate 
crystals in vitro [9,10], and was able to directly 
inhibit the binding of calcium oxalate crystals to 
cultured renal epithelial cells [11]. Therefore, 
OPN is an important modulator of stone 
formation. Mutations in the gene directing the 
synthesis of OPN may predispose to AS. 
 
Recently, -443T/C polymorphisms on the 
promoter region of OPN gene have been found 
to affect gene expression and transcriptional 
activity [12,13], and have been found to 
associate with several diseases, including 
pseudoxanthoma elasticum [14], stroke [15], and 
chronic hepatitis C [16]. The -443 T/C 
polymorphism influenced the binding of MYT1 
zinc finger factor, which is associated with 
neurogenesis [17]. In chronic hepatitis C 
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patients, the -443T/C polymorphism could be a 
marker reflecting hepatitis activity [18]. 
 
AS patients’ disease severity is largely 
genetically determined [19]. However, there are 
no relative reports about the relationship 
between OPN polymorphisms and risk of AS 
currently. Previous study confirmed that OPN is 
overexpressed and with higher levels in AS 
patients compared with controls [20,21]. 
However, there have been no studies 
investigated the association of polymorphisms of 
OPN gene with AS to date. Therefore, we 
conducted a hospital-based case-control study to 
investigate the association of polymorphisms of 







A case-control study was conducted between 
May 2010 and October 2012. A total of 120 
unrelated AS patients included 78 men and 42 
women with mean age of  39.5 ± 10.3 years 
(range 18-52 years, all the patients were HLA-
B27 positive) and 106 normal control included 71 
men and 35 women with mean age of 35.8 ± 
11.5 years (range 15 - 48 years). All the subjects 
were recruited after giving written informed 
consent. This study was approved by Ethics 
Committee of Autonomous Region People's 
Hospital (approval ref. no. 20100301) [22].  
 
Analysis of OPN gene polymorphisms  
 
Three milliliters of fasting venous blood were 
collected from all subjects. Genomic DNA was 
extracted from the white blood cells following 
standard protocols. SNP was determined using 
direct sequencing of the sense and anti-sense 
strands following polymerase chain reaction 
(PCR) amplification of the promoter regulatory 
region -532 to +94. PCR was performed using 50 
ng DNA as a template under the following 
conditions: 94 °C for 7 min, then 30 cycles of 94 
°C for 55 s, an annealing temperature for 50 s 
and 72 °C for 90 s, with a final extension at 72 °C 
for 10 min. The PCR products were subjected to 
cycle sequencing with the respective forward and 
reverse primer using an automated ABI 3100 





Statistical analysis was performed using SPSS 
11.5 software. One-way ANOVA and t-test were 
used to compare mean differences for 
continuous variables. Allele frequency was 
determined via direct counting. Statistical 
significance of differences in gene and genotype 
frequencies between patients and controls was 
evaluated for each polymorphism using Chi-
square test with Yates’ correction, and 




OPN genotype and allele frequencies 
 
The OPN genotype was conducted using direct 
sequencing of DNA fragments from the promoter 
regulatory region -532 to +94 in AS patients and 
controls. The frequency of SNP at -443 with CC 
homozygotes in AS patients was 0.7083 and 
0.8396 in the control (Figure 1). 
 
OPN polymorphism is associated with AS 
susceptibility 
 
As shown in Table 1, T frequency was 
significantly increased in AS patients (18.75) 
compared to the control (10.85, p < 0.05), the 
rate of the CT+TT genotype in AS patients was 
significantly higher than in those with CC 
genotype compared with control (p < 0.05), 
indicating that subjects who carried T allele have 
a significantly higher risk of developing AS than 
in those with C allele. 
 
      
Figure 1: Schematic diagram and sequencing data of OPN. Note: A = C/C homozygotes; B = C/T 
Heterozygotes; C = T/T homozygotes 
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     Table 1: Allele frequency of OPN polymorphism detected in AS patients and controls 
 
Variable AS (n = 120) Control (n = 106)  P-value 
Allele, n(%) 
  C 
  T 
Genotype, n(%) 
  CC                                                           
  CT 









   189(89.15)            
    23(10.85) 
 
   89(83.96) 
   11(10.38)                          
    6(5.66) 
 
       








The pathogenesis of AS remains poorly 
understood. However, genetic factors play a 
significant role [23]. Single nucleotide 
polymorphisms (SNP) of the human OPN gene 
have been reported to be associated with many 
diseases [24,25]. Based on current literature, this 
is the first time to report the relationship between 
OPN polymorphism and AS patients.  
 
In this study, we have investigated the difference 
in OPN gene polymorphisms between AS 
patients and healthy controls. The T frequency 
was significantly increased in AS patients 
compared to the control (p < 0.05), the rate of the 
CT+TT genotype in AS patients was significantly 
higher than those with CC genotype compared 
with the control (p < 0.05), indicating that 
subjects who carried the T allele had a 
significantly higher risk of developing AS than 
those with the C allele. Dong et al found that the 
genetic variation at locus -443 of the OPN 
promoter plays important roles in the regulation 
of OPN expression and cancer progression of 
hepatocellular carcinoma (HCC), which is a novel 
determinant and target for HCC metastasis and 
prognosis [26]. Hao et al found that OPN -443C 
> T gene polymorphism may be used as a 
molecular marker to predict the treatment 
response to chemotherapy in advanced non-
small-cell lung cancer patients [27]. Zhao et al 
found that OPN -443 C/T polymorphism is a 
potential predictive marker of metastasis and 
poor prognosis in intrahepatic 
cholangiocarcinoma patients [28]. 
 
So far, genetic variants in OPN gene have been 
shown to be involved in susceptibility to other 
immune-mediated diseases such as SLE [29,30], 
oligoarticular juvenile idiopathic arthritis [31] and 
sarcoidosis [32]. Despite promising functional 
data, previous genotype analyses could not 
confirm SPP1 as significant disease modifying 
gene in classical Th17-mediated diseases such 
as multiple sclerosis [33,34] and rheumatoid 
arthritis [35]. However, it is first time to report the 
relationship between OPN polymorphism and AS 
patients. It is expected that this study should be 
confirmed in a large and ethnically divergent 
population in order to make a stronger 
conclusion about the association between -443 
polymorphism with AS.   
 
Limitation of the study 
 
In this study, the sample size of participants was 
small, thus rendering the results liable to bias. 





SNP at nt -443 of the OPN gene can serve as a 
candidate genetic marker to evaluate the risk of 
AS. Subjects who carry T allele may have a 
significantly higher risk of developing AS. This 
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